Sponsored by Cutera
Cutera (Brisbane, Calif.) is redefining aesthetic treatments with AviClearTM, reportedly the first and only energy-based device cleared by the FDA for the treatment of mild, moderate and severe acne vulgaris. Unlike current standard acne treatments, AviClear utilizes 1726 nm laser energy to reduce the severity and frequency of acne, providing a drug-free alternative that can treat all skin types. Soon physicians will be able to add this modern alternative to their current armamentarium of acne treatments.
The excitement grows as the first patients have now been treated with AviClear. Julie Harper, MD (Birmingham, Ala.), past president of the American Acne and Rosacea Society, shared that she was looking forward to having a new, drug-free alternative for treating acne of all severities and skin types. “We have many effective topical and oral pharmaceutical products for acne, but patients sometimes need or want an alternative. There are patients who have tried all available treatments and have not achieved their desired results,” she explained. “AviClear will give us another tool to help these patients achieve acne clearance with an enduring response.”
Acne vulgaris is a common skin concern, especially among young adults. AviClear is a first-of-its-kind treatment that targets and suppresses the sebaceous glands to resolve active acne and help prevent future breakouts. With just three 30-minute sessions, 80% of patients treated with AviClear saw at least half of their acne clear in the first three months following treatment, with results continuing to improve over time, indicating durability of results and long-term efficacy.1
Dr. Harper reported that her patients tolerated AviClear very well, thanks to the AviCoolTM contact cooling feature. “The discomfort was only during the laser pulse, and there was no residual discomfort or redness. The full-face treatment took about 25 minutes.” Cutera has reported that no pain mitigation was utilized or required by any clinical study participant, nor were there any reportable events observed during the clinical trial.2
AviClear offers a safe and effective solution to acne vulgaris and will be available to physicians throughout the U.S. over the course of 2022. Cutera plans to provide a comprehensive support program to help providers acquire and market the system to their patients. Aesthetic practices will benefit from an enhanced portfolio of treatments for acne patients that can be used alone or in combination with other therapies. “I will likely use AviClear both as a monotherapy in some patients who want the ease of a ‘no homework’ treatment, and in combination with other treatments,” Dr. Harper added.
With no downtime and no adverse events throughout the trials, AviClear should prove to be a game changer for physicians and their treatment of acne vulgaris. Cutera’s AviClear and the AviCool feature will benefit both physicians and their patients, making this unique device a soon-to-be standard treatment in the future of aesthetic medicine.
References:
1. Data on file. FDA clearance study. Cutera Inc.
2. Data on file. Cutera Inc.
